BioAtla BCAB 深 沪
等待开盘 11-04 09:30:00 美东时间
0.6644
-0.035
-5.00%
华盛通- 最 高0.72
- 今 开0.671
- 成交量 59.92万股
- 最 低 0.6501
- 昨 收 0.6994
- 总市值 3901.46万
- 52周最高 2.525
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.24
- 委 比 1.68%
- 总股本 5872.16万
- 历史最高 76.63
- 量 比 0.88
- 振 幅 9.99%
- 历史最低 0.24
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
BioAtla presents clinical data on Ozuriftamab Vedotin (Oz-V), a novel antibody-drug conjugate targeting ROR2 in HPV+ oropharyngeal cancer, at the IPVS Conference in Bangkok. The poster highlights Oz-V's mechanism, clinical results showing an overall response rate of 45%, and plans for a Phase 3 trial in early 2026. OPSCC, driven by HPV, is a significant and underserved cancer population with poor prognosis. Oz-V has received FDA Fast Track Design...
10-23 12:00
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
BioAtla, Inc. announced preliminary results from a Phase 1 study of BA3182, a dual-conditional binding bispecific T-cell engager targeting EpCAM and CD3, designed to selectively bind in acidic tumor microenvironments to minimize off-tumor toxicity. The study demonstrated manageable safety, with transient adverse events and minimal cytokine release syndrome (CRS). Efficacy showed prolonged tumor control, including a confirmed partial response (cPR...
10-20 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
BioAtla Will Present Clinical Data For Its Investigational Axl-Targeting Antibody-Drug Conjugate Mecbotamab Vedotin At The SITC 2025 Annual Meeting
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of
10-03 21:03
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
BioAtla, Inc. announced that clinical data for its AXL-targeting ADC, mecbotamab vedotin (BA3011), will be presented at the SITC 2025 Annual Meeting. The presentation by Dr. Mihaela Druta of Moffitt Cancer Center on November 7 will highlight a median OS of 21.5 months in 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. The abstract (#523) will be featured in the poster session. BioAtla, ...
10-03 13:00
BioAtla Highlights FDA Alignment On Phase 3 Ozuriftamab Vedotin Trial Design; Says Co Continues Preparations For Enabling Initiation Of Phase 3 Study; Co Maintains Previous Guidance
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3
09-08 20:07
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
BioAtla announced FDA alignment on the Phase 3 design for Ozuriftamab vedotin (Oz-V), including dosing and endpoints for potential accelerated approval. The company plans to initiate the Phase 3 study early next year with a strategic partner. Oz-V, a CAB-ADC targeting ROR2, showed promising results in HPV+ OPSCC with a 45% ORR and 11.6-month median OS in Phase 2 trials. FDA recommends a pivotal trial with 300 patients comparing Oz-V to standard t...
09-08 12:00
JMP Securities Downgrades BioAtla to Market Perform
JMP Securities analyst Reni J. Benjamin downgrades BioAtla (NASDAQ:BCAB) from Market Outperform to Market Perform.
08-13 22:15
跨国药企洞察｜默沙东终止康方2亿美元合作项目，跨国药企如何“优中选优”？
（来源：动脉新医药） 编者按： 全球视野下的跨国药企深度洞察——创新、博弈与中国答卷 在全球医药产业发展的宏大叙事中，跨国药企始终扮演着关键角色——他们...
08-12 08:02
H.C. Wainwright Reaffirms Their Hold Rating on BioAtla (BCAB)
H.C. Wainwright analyst Arthur He CFA maintained a Hold rating on BioAtla today...
08-11 18:18
